Leqvio Insurance Denied? How to Appeal Your Inclisiran Denial

Leqvio (inclisiran) is a first-in-class small interfering RNA (siRNA) therapy that lowers LDL cholesterol by blocking the production of PCSK9 in the liver — and it only needs to be injected twice a year after two initial doses. FDA-approved for adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH), Leqvio represents a significant therapeutic advance. Despite this, insurance denials are common. Here's how to fight back.

What Leqvio Treats and Why Patients Need It

Leqvio works differently from traditional PCSK9 inhibitors like Repatha and Praluent. Instead of blocking the PCSK9 protein after it's made, inclisiran targets the RNA instructions that tell liver cells to make PCSK9 in the first place. The result is a sustained 50%+ LDL reduction from just two injections per year.

Leqvio is FDA-approved for:

• Adults with established ASCVD (history of MI, stroke, or peripheral artery disease) who need additional LDL lowering on maximally tolerated statin therapy
• Adults with HeFH who need additional LDL lowering

The twice-yearly dosing schedule has meaningful advantages: fewer injections, improved adherence, and no risk of patients running out of medication or missing doses. For patients who have struggled with adherence to monthly biologic injections, Leqvio offers a compelling alternative.

Common Denial Reasons for Leqvio

Step therapy: Insurers typically require patients to demonstrate failed or inadequate response to maximally tolerated statin therapy and ezetimibe before approving Leqvio. Some plans also require a failed trial of a PCSK9 monoclonal antibody (Repatha or Praluent) first.

Novel therapy / insufficient evidence: Some plans classify inclisiran as too new or experimental despite its FDA approval and robust ORION trial program. This is a weak argument that should be challenged directly.

Formulary exclusion: Leqvio may simply not be on your plan's formulary, especially since it was approved in late 2021 and formulary additions take time.

LDL threshold not met: Like other PCSK9-based therapies, plans often require LDL to remain above a threshold (commonly ≥70 mg/dL) despite optimized statin therapy before approving inclisiran.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denied: PA is universally required. Denials often result from incomplete documentation of cardiovascular history, statin therapy, and current LDL.

Step-by-Step: How to Appeal a Leqvio Denial

Step 1: Get the denial reason in writing. Whether it's step therapy, formulary exclusion, or PA, you need the specific reason before crafting your appeal.

Step 2: Document your full lipid management history. Every statin tried, dose, duration, and LDL result. Ezetimibe use. Any PCSK9 inhibitor trials if required by the plan.

Step 3: Obtain a Letter of Medical Necessity from your cardiologist or lipidologist. The LMN should explain your ASCVD or HeFH diagnosis, LDL levels on current therapy, prior therapies and their outcomes, and why inclisiran is the appropriate next step.

Step 4: Address the "novel therapy" argument directly if raised. Include the ORION-10 and ORION-11 trial data in your submission. These Phase 3 trials demonstrated robust LDL reduction and cardiovascular safety that led directly to FDA approval.

Step 5: File the internal appeal with all documentation. Request peer-to-peer review for your physician to speak with the plan's medical director.

Step 6: If denied internally, file an external appeal. External Independent Review: Complete Guide" class="auto-link">External reviewers consider FDA approval and clinical evidence without the plan's cost incentives.

What to Include in Your Leqvio Appeal Letter

• Policy number, member ID, claim reference, and date of denial
• Leqvio (inclisiran) prescribed dose and indication
• Cardiovascular history: established ASCVD (MI, stroke, PAD) or HeFH diagnosis
• LDL levels over time on statin therapy
• Statin therapy history: drugs, doses, duration, LDL response, tolerability issues
• Ezetimibe trial documentation
• Letter of Medical Necessity from cardiologist or lipid specialist
• ORION-10 and ORION-11 clinical trial references
• ACC/AHA cholesterol guideline citations supporting PCSK9-pathway therapies
• Counter-argument to any "experimental" or "insufficient evidence" denial reasons

Success Tips for Leqvio Appeals

Challenge "experimental" claims with FDA approval. Leqvio received FDA approval in December 2021 based on Phase 3 outcomes data. If a plan calls it experimental, cite the approval directly and note that the FDA's review process provides the highest evidentiary standard in medicine.

Highlight the adherence advantage. For patients with adherence challenges or who prefer fewer injections, inclisiran's twice-yearly dosing is a meaningful clinical distinction from monthly biologics. If adherence has been a documented challenge, make that part of the LMN.

Show your cardiovascular risk score. Use the ACC/AHA Pooled Cohort Equation or similar tools to quantify your 10-year cardiovascular risk. Very-high-risk patients with established ASCVD and persistently elevated LDL have the strongest coverage argument.

Know if FH genetic testing helps. If you have HeFH, genetic testing confirming an LDLR, APOB, or PCSK9 mutation can be powerful evidence that your elevated LDL is genetic — not just lifestyle-related — and requires aggressive pharmacotherapy.

Fight Back With ClaimBack

Leqvio is an FDA-approved medication that your cardiologist has determined is necessary for your cardiovascular health. Don't accept an insurance denial as the final answer. ClaimBack helps you organize your appeal and fight back effectively.

Start your Leqvio appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied